Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED STATEMENTS OF CHANGES IN SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY

v3.25.1
CONSOLIDATED STATEMENTS OF CHANGES IN SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Treasury Stock
Preferred Stock
Total
Balances, Ending (in Shares) at Dec. 31, 2023             0
Balances, Ending (in Shares) at Dec. 31, 2023             0
Balances, Beginning at Dec. 31, 2022 $ 73 $ 63,499,628 $ (56,173,207)       $ 7,326,494
Balances, Beginning (in shares) at Dec. 31, 2022 733,215            
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common shares under Sales Agreement, net of costs $ 3 1,156,440         1,156,443
Issuance of common shares under Sales Agreement, net of costs (in shares) 25,675            
Exercise of warrants $ 2 299,127         299,129
Exercise of warrants (in shares) 19,145            
Shares surrendered in cashless warrant exercises $ (1)       $ (299,128)   (299,129)
Shares surrendered in cashless warrant exercises (in shares) (7,718)            
Share-based compensation expense   619,972         619,972
Net loss     (5,296,015)       (5,296,015)
Balances, Ending at Dec. 31, 2023 $ 77 65,575,167 (61,469,222)   (299,128)   $ 3,806,894
Balances, Ending (in shares) at Dec. 31, 2023 770,317            
Balances, Ending (in Shares) at Dec. 31, 2024           2,213.8044 2,213.8044
Increase (Decrease) in Temporary Equity [Roll Forward]              
Temporary Equity, Issuance of stock in connection with the acquisition of Pharmagesic           $ 70,372,634  
Temporary Equity, Issuance of stock in connection with the acquisition of Pharmagesic (in shares)           2,108.3854  
Temporary Equity, Transaction costs paid through the issuance of stock           $ 3,518,623  
Temporary Equity, Transaction costs paid through the issuance of stock (in shares)           105.419  
Temporary Equity, Accrual of paid-in-kind dividends on Serise A Non-Voting Convertible Preferred Stock           $ 514,105 $ 514,105
Balances, Ending at Dec. 31, 2024           $ 74,405,362 $ 74,405,362
Balances, Beginning (in Shares) at Dec. 31, 2023             0
Balances, Ending (in Shares) at Dec. 31, 2024           2,213.8044 2,213.8044
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Proceeds from public offering of common stock, net of offering costs $ 34 1,382,136         $ 1,382,170
Proceeds from public offering of common stock, net of offering costs (shares) 340,000            
Issuance of stock in connection with the acquisition of Pharmagesic $ 21 893,072         893,093
Issuance of stock in connection with the acquisition of Pharmagesic (in shares) 211,383            
Transaction costs paid through the issuance of stock $ 1 44,649         44,650
Transaction costs paid through the issuance of stock (in shares) 10,568            
Payout of fractional shares in connection with reverse stock split   (351)         (351)
Payout of fractional shares in connection with reverse stock split (in shares) (90)            
Accretion of redeemable convertible preferred stock to redemption value   (514,105)         (514,105)
Share-based compensation expense   476,021         476,021
Net loss     (12,349,724)       (12,349,724)
Accumulated other comprehensive income       $ (3,862,987)     (3,862,987)
Balances, Ending at Dec. 31, 2024 $ 133 $ 67,856,589 $ (73,818,946) $ (3,862,987) $ (299,128)   $ (10,124,339)
Balances, Ending (in shares) at Dec. 31, 2024 1,332,178